Dhanuka Agritech Ltd

Q2 FY23 Earnings Call Analysis

Fertilizers & Agrochemicals

Full Stock Analysis
fundraise: No informationcapex: Yesrevenue: Category 3margin: Category 1orderbook: No information
💰

fundraise

Any current/future new fundraising through debt or equity?

The transcript from the Dhanuka Agritech Limited Q1 FY24 earnings call on August 2, 2023, does not mention any specific plans or discussions related to new fundraising through debt or equity, either current or future. Key points relevant to funding or capital expenditure include: - The company is looking at further capital expenditure over the next two years to establish more production capacity. - Current market forces are unfavorable, but price stabilization and improvement in margins are expected. - No explicit mention of raising funds through equity or debt instruments was made during the call. - Focus remains on margin improvement, production capacity expansion, and sustaining business growth through operational means. Hence, based on the available information, there is no indication of any new fundraising via debt or equity at present or in the near future.
🏗️

capex

Any current/future capex/capital investment/strategic investment?

- The company is progressing on its technical plant at Dahej, with production expected to start in the third week of August. - Production capacity at Dahej is planned at around 600 metric tons annually, targeting an initial production of 350 metric tons this financial year. - The Dahej plant will begin with bio-cyhalothrin and Lambdacyhalothrin technicals, supporting long-term business and export growth. - Over the next two years, further capex is planned to expand production capacity, depending on market conditions. - Current market forces are unfavorable but expected to improve; price stabilization is underway. - The plant is expected to reach around 80% capacity utilization next year, with revenue from the Dahej plant anticipated between INR 80 crores to INR 100 crores. - The capex and strategic investments align with government initiatives and opportunities arising from China+1 supply chain shifts.
📊

revenue

Future growth expectations in sales/revenue/volumes?

- Positive demand outlook expected for the year ahead with anticipated double-digit industry volume growth. - Q2 starting strong with improved farmer consumption and channel inventory normalization post-Q1 sluggishness. - Revenue growth guidance around 10% for the current financial year, including new synthetic pyrethroids plant revenues. - Synthetic pyrethroids plant at Dahej expected to generate about INR 50 crores revenue in the current year and ramp up to 80% capacity next year, corresponding to INR 80-100 crores revenue. - Export revenue expected around INR 30 crores for FY23-24, focusing on both formulations and technical products. - Gross margins anticipated to expand by approximately 200 bps for the full year, driven by price stabilization and product mix improvements. - Agricultural sector expected to benefit from good monsoon and positive commodity pricing, supporting overall agri-input consumption growth.
📈

margin

Future growth expectations in earnings/operating earnings/profits/EPS?

- Management expects a positive demand scenario and aims to upgrade gross margin by about 200 basis points for the full year. - EBITDA for the current financial year is expected to be negative, but the company anticipates positive EBITDA within the next 2-3 years. - Revenue guidance includes about INR 50 crores from the synthetic pyrethroids plant starting commercial production, with expected full utilization of the Dahej plant (80% capacity) next year leading to revenue of INR 80-100 crores. - Price declines have mostly stabilized; margins are expected to improve in Q2 and beyond due to recovering consumption and better price trends. - Export revenue is expected to be around INR 30 crores for the full year. - The company aims for double-digit industry volume growth and anticipates favorable market conditions ahead, supporting earnings growth.
📋

orderbook

Current/ Expected Orderbook/ Pending Orders?

- The company expects a production of about 350 metric tons from the synthetic pyrethroids plant in the current financial year. - This production translates to approximately INR 50 crores in revenue for the year. - The annual production capacity of the plant is about 600 metric tons. - There is no specific mention of a current or expected order book or pending orders in exact figures within the provided transcript. - However, a positive outlook is indicated for export opportunities, with India becoming the second largest agrochemical exporter. - The company is looking beyond neighboring countries for export and is open to various markets globally.